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Metformin, a diabetes drug with well-established side
effect and safety profiles, has been widely studied
for its anti-tumor activities in a number of cancers,
including breast cancer. But its mechanism of action
in the clinical arena remains elusive. In a window of
opportunity trial of metformin in non-diabetic breast
cancer patients, Dowling and colleagues examined
both the direct actions of the drug on cancer cells
(as mediated by AMP kinase), as well as its indirect
actions (as mediated by circulating insulin). The data
suggest that short-term administration of metformin in
this setting has anti-tumor effects significantly involving
the indirect, insulin-dependent pathway. The role of the
direct pathway remains to be determined. This study
represents an important step forward in establishing
one of several possible mechanisms for metformin,
information that will be useful in determining
candidate biomarkers to evaluate in large clinical trials
of metformin, such as the ongoing NCIC CTG MA.32
trial of adjuvant metformin. The potential significance
of these data for metformin in the treatment of breast
cancer is discussed here.assessed individually, the largest decreases in serum insu-
lin, tumor IR, and p-Akt (via a summary score of all threeMetformin has been studied in breast cancer, but its
mechanism of action in the clinical arena remains
unclear. Several trials have attempted to address this
knowledge gap (Table 1) [1–10]. In a recent issue of
Breast Cancer Research, Dowling and colleagues [10]
present their mechanistic studies from a previously re-
ported single arm, neoadjuvant, window of opportunity
trial of metformin in non-diabetic breast cancer patients.
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creativecommons.org/publicdomain/zero/1.0/metformin 500 mg three times daily for a median of
18 days (range 13 to 40). Their results demonstrate that
short-term administration of metformin in this setting
has anti-cancer properties significantly involving indirect
actions of metformin.
By binding to its receptor, insulin has been shown to
have mitogenic and anti-apoptotic effects in several
cancers, including breast cancer, and circulating insulin
is associated with increased cancer risk and prognosis
[11]. In their previous publication on the same trial [9],
the authors reported significant decreases in weight,
body mass index (BMI), glucose, homeostatic model
assessment (HOMA), and tumor cell proliferation by
Ki-67, as well as an increase in apoptosis by TUNEL
(terminal deoxynucleotidyl transferase (TdT) dUTP
nick-end labeling) after metformin treatment. In the
current study, they point to the insulin-dependent ef-
fects of metformin based on the decrease in insulin
receptor (IR) expression in tumors together with reduc-
tions in Akt and ERK1/2 phosphorylation (key down-
stream effectors of phosphatidylinositol 4,5-bisphosphate
3-kinase (PI3K)/Akt and Ras-mitogen-activated protein
kinase (MAPK) signaling pathways, respectively). Further-
more, in an important analysis, when patients were
variables) correlated with the largest decreases in tumor
cell proliferation. However, overall changes in Akt and
ERK1/2 phosphorylation did not correlate with reductions
in circulating insulin levels, suggesting that these changes
were also mediated by additional (unexplored) insulin-
independent pathways.
The decreases in Akt and ERK1/2 phosphorylation are
in agreement with previous in vitro and in vivo breast
cancer studies [12, 13]. Likewise, the decreases in IR ex-
pression and p-Akt are consistent with a two arm win-
dow of opportunity trial conducted by Bonanni and
colleagues [4], where non-diabetic women with breast
cancer were randomized to metformin or no drug. In
that study, a non-significant decrease in IR and as article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Metformin trials in non-diabetic breast cancer patients
Study/reference Number of women Study population Setting Design Metformin dosing Weight Serum glucose
Goodwin et al. 2008 [1] 22 Early BC patients; insulin
>45 pmol/L
Adjuvant Single arm 500 mg tid × 6 mos ↓ ○
Hadad et al., 2011 [2],
Hadad et al. 2015 [3]
8 + 47 Operable invasive BC Neoadjuvant window Metf versus ctrl
(no metf)
500 mg qd × 1 wk, then
1000 mg bid × 1 wk
Bonanni et al. 2012 [4],
Cazzaniga et al. 2013 [5],
DeCensi et al. 2014 [6]
200 Operable BC Neoadjuvant window Metf versus ctrl
(placebo)
850 mg bid × 4 wks ↓ in BMI > 27
Kalinsky et al. 2014 [7] 35 Ov/Ob invasive BC or
DCIS versus matched
untreated historical ctrl
Neoadjuvant window Single arm 500 mg am and 1000 mg pm,
2–4 wks (avg = 22 days)
↓ ○
Goodwin et al. 2015 [8] 3,649 Treated early BC Adjuvant Metf versus ctrl
(placebo)
850 mg bid × 5 yrs
(results reported after 6 mos)
↓ ↓
Niraula et al. 2012 [9],
Dowling et al. 2015 [10]
39 Operable BC Neoadjuvant window Single arm 500 mg tid 13–40 days
(avg = 18)
↓ ↓




Goodwin et al. 2008 [1] ↓ ↓
Hadad et al., 2011 [2],
Hadad et al. 2015 [3]
○ in metf, ↑ in ctrl ↓ in metf, ○ in ctrl ↓Cleaved Caspase-3 NS ↓ IR; ↓ pAkt ↑p-AMPK
Bonanni et al. 2012 [4],
Cazzaniga et al. 2013 [5],
DeCensi et al. 2014 [6]
NS ↓ in BMI > 27 ○ metf versus ctrl; NS ↓ in HOMA
> 2.8 and NS ↑ in HOMA < 2.8
TUNEL ↑ in both metf and ctrl ↓IGFBP-1
Kalinsky et al. 2014 [7] NS ↓ NS ↓ ○ ○ IGFBP-3
Goodwin et al. 2015 [8] ↓ ↓
Niraula et al. 2012 [9],
Dowling et al. 2015 [10]
NS ↓ ↓ Largest ↓ in patients with largest ↓
in insulin, IR, and pAkt
TUNEL ↑ ↓ IR, pAkt, and pERK1/2 ↓ pAMPK and pACC; all tumors
expressed OCT1
Down arrows indicate decrease; circles indicate no change; up arrows inidcate increase. ACC, acetyl-CoA carboxylase; AMPK, AMP-activated protein kinase; avg, average; BC, breast cancer; bid, twice a day; BMI, body
mass index; ctrl, control; DCIS, ductal carcinoma in situ; ERK, extracellular signal-regulated protein kinase; HOMA, homeostatic model assessment; IGFBP, insulin-like growth factor-binding protein; IR, insulin receptor;
metf, metformin; mos, months; NS, non-significant; Ob, obese; OCT, organic cation transporter; Ov, overweight; qd, once a day; tid, three times a day; TUNEL, terminal deoxynucleotidyl transferase (TdT) dUTP nick-end
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min group, while non-significant increases were found
in the control group. In future studies, it would be inter-
esting to analyze activated (phosphorylated) IR staining
in tumors to further define the role of this signaling axis.
Metformin can also exert its anti-tumor activity
through insulin-independent direct actions on cancer
cells. The most studied pathway involves the serine/
threonine kinase AMP-activated protein kinase (AMPK),
a metabolic master switch which is activated in low en-
ergy states. Upon activation, AMPK increases cellular
energy levels by inhibiting energy-consuming anabolic
pathways and stimulating energy-producing catabolic
pathways. The role of AMPK in tumorigenesis is the
subject of ongoing investigation. Metformin has been
shown to activate AMPK in both cancer and non-cancer
settings. This includes a window of opportunity trial by
Hadad and colleagues [3], where treated patients showed
significant upregulation of p-AMPK compared with the
control group. In the current study, contrary to expect-
ation, the authors found a decrease in the activation of
AMPK and one of its targets (acetyl-CoA carboxyla-
se(ACC)) upon treatment with metformin, as well as a
high baseline level of AMPK. A similar result was ob-
tained in a window of opportunity study in endometrial
cancer [14]. The explanation for this paradoxical result
is unclear. However, it is known that metformin may
have both AMPK-dependent and AMPK-independent
anti-tumor effects in different contexts [15]. AMPK-
independent effects were not examined in the current
study and should be the subject of future investigations
of the direct effects of metformin in breast cancer.
The current study has a number of strengths. Met-
formin was administered as close as possible to
the time of tumor tissue acquisition, which may be
critical for accurate measurement of biomarkers. The
analysis in individual patients to correlate several
biomarkers (serum insulin, and tumor IR and p-Akt,
with tumor Ki-67) is a compelling one. Limitations
include small sample size and lack of no treatment
controls, so that the results will need to be validated
in larger trials. The study suggests some additional ana-
lyses to keep in mind for future trials. The pharmacol-
ogy of metformin in the cancer setting is largely
unexplored. It would be interesting to see whether
dividing the wide range of metformin treatment time
(13 to 40 days) into groups of shorter and longer dur-
ation or into high versus low OCT1 expression levels
would reveal differences in biomarkers according to
these parameters.
In summary, in combination with the results from the
trials listed in Table 1, the results of Dowling et al.
strongly suggest that metformin exerts a significant
part of its anti-tumor effects in breast cancer via theindirect pathway by lowering serum insulin, inhibiting
downstream signaling via PI3K/Akt and Ras-MAPK
pathways, and leading to decreases in cell proliferation.
This information has important implications for the con-
duct and analysis of ongoing and future clinical trials of
metformin. A number of trials are currently underway
evaluating metformin in breast cancer (clinicaltrials.gov).
The largest and most advanced is the NCIC CTG MA.32,
an ongoing adjuvant trial of 3,649 women with early
stage breast cancer examining the effects of metformin
versus placebo on survival and other outcomes. An initial
report has been published showing that metformin sig-
nificantly improved metabolic parameters such as weight,
insulin, glucose, leptin, and C-reactive protein (CRP) at 6
months, regardless of initial weight or degree of insulin
resistance [8]. The results of the current study suggest
that serum insulin and tumor IR, p-Akt, and Ki-67
should be evaluated as potential biomarkers of metfor-
min tumor sensitivity in this and other metformin trials
in breast cancer. The role of the direct effects of metfor-
min on breast cancer cells, whether mediated via AMPK
or otherwise, remains an open question to be explored in
future pre-clinical and clinical studies. These and other
studies will undoubtedly contribute to the evolving mys-
tery of this fascinating drug.
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